suPAR to Risk-Stratify Patients With Malaria
Veselina Stefanova1, Valerie M Crowley2,3, Andrea M Weckman1,2,3
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Insights
Soluble urokinase-type plasminogen activator receptor (suPAR) shows promise as an early predictor for severe malaria outcomes in children. This biomarker could improve risk assessment and management strategies for severe malaria.
Area of Science:
- Immunology
- Infectious Diseases
- Biomarker Discovery
Background:
- Severe malaria (SM) is a major global health threat, especially for children in sub-Saharan Africa.
- Current diagnostic tools lack the ability to accurately predict severe outcomes or mortality in pediatric malaria cases.
- Pathogenesis of SM involves complex host immune responses and endothelial activation.
Purpose of the Study:
- To review the evidence for soluble urokinase-type plasminogen activator receptor (suPAR) as an early prognostic biomarker for severe and fatal malaria.
- To explore the potential clinical utility of suPAR in malaria triage and patient management.
Main Methods:
- Literature review of studies investigating suPAR in the context of malaria.
- Analysis of research implicating immune and endothelial activation markers in SM pathogenesis.
- Evaluation of suPAR's predictive value for disease progression and mortality.
Main Results:
- suPAR is emerging as a novel and early predictor of severe and fatal malaria.
- Measuring suPAR levels at presentation may offer valuable prognostic information.
- suPAR's role in identifying high-risk patients warrants further investigation.
Conclusions:
- suPAR demonstrates significant potential as a prognostic biomarker for severe malaria.
- Integrating suPAR measurement into clinical practice could enhance malaria risk stratification.
- Further research is needed to fully establish suPAR's utility in malaria management and public health strategies.
Abstract:
Severe malaria (SM) is a leading cause of global morbidity and mortality, particularly in children in sub-Saharan Africa. However, existing malaria diagnostic tests do not reliably identify children at risk of severe and fatal outcomes. Dysregulated host immune and endothelial activation contributes to the pathogenesis of SM. Current research suggests that measuring markers of these pathways at presentation may have clinical utility as prognostic indicators of disease progression and risk of death. In this review, we focus on the available evidence implicating soluble urokinase-type plasminogen activator receptor (suPAR) as a novel and early predictor of severe and fatal malaria and discuss its potential utility for malaria triage and management.
